Eli Lilly (LLY) is back above $1 trillion, closing at its first record high since November, as Wall Street starts pricing in a drug many investors may not know yet: Reta.
The stock is up more than 25% since the market’s March 30 low and more than 400% over the past five years, turning Eli Lilly into the market’s clearest bet on the next phase of the GLP-1 boom.
Reta is shorthand for retatrutide, Eli Lilly’s experimental next-generation obesity drug. It is not approved yet, but the data is already pulling Wall Street’s attention beyond today’s GLP-1 leaders.
The drug targets three hormone pathways involved in appetite, blood sugar regulation, and energy use. That is the key difference from Eli Lilly’s approved obesity and diabetes drugs, Zepbound and Mounjaro, which target two pathways.
The trial numbers explain the buzz. In Eli Lilly’s phase 3 TRIUMPH-1 obesity trial, patients on the highest dose lost an average of 70.3 pounds, or 28.3% of body weight, over 80 weeks. More than 45% of patients on that dose lost at least 30% of their body weight, a level Eli Lilly said has long been associated with bariatric surgery.
That is why Reta is moving the stock, not just the drug-development calendar.
Investors are paying for the possibility that GLP-1s and related drugs become a broader metabolic platform — one that stretches from obesity and diabetes into sleep apnea, kidney disease, heart risk, liver disease, and even addiction research.
That could revive a role GLP-1 makers played early in the bull market that began in late 2022, when Eli Lilly and Novo Nordisk (NVO) offered investors a rare healthcare growth trade that could sit alongside megacap tech. Amgen (AMGN) and Viking Therapeutics (VKTX) are also part of the obesity-drug race, but Eli Lilly remains the stock with the clearest power to move the market-cap math.
The ripple effects are already showing up outside healthcare. Packaged food, alcohol, restaurant, and retail stocks are all getting pulled into the same debate over what happens when appetite and cravings change. Campbell’s (CPB) recently hit historic lows, while Diageo (DEO) and other alcohol names remain far below their peaks.
For Eli Lilly bulls, the next test is the old high near $1,100. A breakout above that level would put the stock back in record territory and make healthcare harder to ignore as an S&P 500 (^GSPC) leadership group. Another rejection there would leave the chart looking more like a potential double-top pattern.
Jared Blikre is the global markets and data editor for Yahoo Finance. Follow him on X at @SPYJared or email him at jaredblikre@yahooinc.com.
Click here for in-depth analysis of the latest stock market news and events moving stock prices
Read the latest financial and business news from Yahoo Finance